Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours

Annals of Oncology

Volumn 24, Issue 10, 2013, Pages 2624-2629

  Cros, J ^a   Sbidian, E ^b   Hans, S ^c   Roussel, H ^a   Scotte, F ^a   Tartour, E ^d   Brasnu, D ^c   Laurent Puig, P ^a   Bruneval, P ^a   Blons, H ^a   Badoual, C ^a,d  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c Gustave Roussy Cancer Campus   (France)

^d PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

Author keywords

C KIT; EGFR; HER2; Malignant salivary gland tumours; Targeted therapies

Indexed keywords

ANDROGEN RECEPTOR; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MUCIN 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; STEM CELL FACTOR RECEPTOR;

ADENOSQUAMOUS CARCINOMA; ADULT; ARTICLE; BRAF GENE; CANCER LOCALIZATION; COHORT ANALYSIS; CONTROLLED STUDY; EGFR GENE; FEMALE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT SALIVARY GLAND TUMOR; MAP2K GENE; MUTATIONAL ANALYSIS; MYOEPITHELIOMA; ONCOGENE; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE NEU; OVERALL SURVIVAL; PI3K GENE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SALIVARY GLAND CARCINOMA; SALIVARY GLAND TUMOR;

C-KIT; EGFR; HER2; MALIGNANT SALIVARY GLAND TUMOURS; TARGETED THERAPIES;

ANDROGEN RECEPTOR ANTAGONISTS; CARCINOMA, MUCOEPIDERMOID; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MYOEPITHELIOMA; ONCOGENES; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; SALIVARY GLAND NEOPLASMS; SURVIVAL; TUMOR MARKERS, BIOLOGICAL;

EID: 84884714043     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt338     Document Type: Article

References (19)

1. Regezi J, Sciubba J, Jordan R. Oral Pathology: Clinical Pathologic Correlations, 4th edition. St Louis, Missouri, USA: Saunders, 2003.
2. Spyratos F, Ferrero-Poüs M, Trassard M et al Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoffvalue. Cancer 2002; 94(8): 2151-2159.
3. Dong P, Xu Z, Jia N et al Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway. Mol Cancer 2009; 8: 103.
4. Ettl T, Schwarz S, Kleinsasser N et al Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology 2008; 53(5): 567-577.
5. Tonon G, Modi S, Wu L et al T(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet 2003; 33(2): 208-213.
6. West RB, Kong C, Clarke N et al MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. Am J Surg Pathol 2011; 35(1): 92-99.
7. Locati LD, Perrone F, Losa M et al Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs). Oral Oncol 2009; 45(11): 986-990.
8. Nasser SM, Faquin WC, Dayal Y. Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am J Clin Pathol 2003; 119(6): 801-806.
9. Jaspers HCJ, Verbist BM, Schoffelen R et al Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options. J Clin Oncol 2011; 29(16): e473-e476.
10. Agulnik M, Cohen EWE, Cohen RB et al Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 2007; 25(25): 3978-3984.
11. Ettl T, Baader K, Stiegler C et al Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer 2012; 106(4): 719-726.
12. Ettl T, Stiegler C, Zeitler K et al EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Hum Pathol 2012; 43(6): 921-931.
13. Kaidar-Person O, Billan S, Kuten A. Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review. Med Oncol 2011. doi:10.1007/s12032-011-9884-1.
14. Hotte SJ, Winquist EW, Lamont E et al Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing C-KIT: a princess margaret hospital phase II consortium study. J Clin Oncol 2005; 23(3): 585-590.
15. Holst VA, Marshall CE, Moskaluk CA et al KIT protein expression and analysis of C-KIT gene mutation in adenoid cystic carcinoma. Mod Pathol 1999; 12(10): 956-960.
16. Siena S, Sartore-Bianchi A, Di Nicolantonio F et al Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101(19): 1308-1324.
17. Locati LD, Bossi P, Perrone F et al Cetuximab in recurrent and/or metastatic salivary gland carcinomas: a phase II study. Oral Oncol 2009; 45(7): 574-578.
18. Janku F, Wheler JJ, Naing A et al PIK3CA mutation H1047R is associated with response to PI3 K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 2012. doi:10.1158/0008-5472.CAN-12-1726
19. Ahmad I, Patel R, Liu Y et al Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis. Cell Death Dis 2011; 2: e124.